Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Regulatory News (OXB)

Share Price Information for Oxford Biomedica (OXB)

Share Price is delayed by 15 minutes
Get Live Data
600.00    2.00 (0.33%)
Bid:
605.00
Ask:
607.00
Spread: 2.00 (0.331%)
Market Cap: £726.22m
OXB Live PriceLast checked at - London Stock Exchange

Intraday Oxford Biomedica Share Chart

2023 AGM Notification

5 May 2023 07:00

RNS Number : 4997Y
Oxford Biomedica PLC
05 May 2023
 

Oxford Biomedica PLC

2023 AGM Notification

London, UK - 5 May 2023: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica", "the Company" or "the Group"), a quality and innovation-led viral vector CDMO, gives notice that the Notice of Annual General Meeting ("AGM") together with a copy of the 2022 Annual report and accounts are being sent to shareholders today. These documents are available on the "Investors" section of the Group's website at www.oxb.com.

In accordance with Listing rule 9.6.1, a copy of the Notice of AGM has been submitted to the Financial Conduct Authority for publication through the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.The Company intends to hold its AGM on Friday 23 June 2023 at the offices of Oxford Biomedica, Windrush Court, Transport Way, Oxford OX4 6LT, commencing at 3:00 p.m.

 

For further information, please contact:

 

Oxford Biomedica plc:

Natalie Walter, Company Secretary

 

Tel: +44 (0)1865 783 000

 

Notes for editors

 

Oxford Biomedica (LSE: OXB) is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

 

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

 

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and a US-based subsidiary, Oxford Biomedica Solutions, based near Boston, MA, US. Learn more at www.oxb.com, www.oxbsolutions.com, and follow us on LinkedIn, Twitter and YouTube.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOAUSAKROUUVRAR
Date   Source Headline
3rd Feb 202011:56 amRNSTotal Voting Rights
3rd Feb 202011:55 amRNSDirector Dealings / Market Share Purchase
22nd Jan 202012:11 pmRNSBlock listing Application
7th Jan 202010:17 amRNSBlock Listing Return
2nd Jan 202011:41 amRNSTotal Voting Rights
19th Dec 20193:27 pmRNSDirector Dealings / Market Share Purchase
19th Dec 20197:00 amRNSExtension of Commercial Supply Agreement
2nd Dec 20199:31 amRNSTotal Voting Rights
27th Nov 201910:05 amRNSDirector Dealings / Market Share Purchase
13th Nov 20194:41 pmRNSHolding(s) in Company
1st Nov 20199:25 amRNSTotal Voting Rights
28th Oct 201912:30 pmRNSDirector Dealings / Market Share Purchase
23rd Oct 20197:00 amRNSHolding(s) in Company
23rd Oct 20197:00 amRNSHolding(s) in Company
16th Oct 20197:30 amEQSHardman & Co Research: Oxford BioMedica (OXB): Demanding second half
1st Oct 201910:18 amRNSTotal Voting Rights
25th Sep 201911:41 amRNSDirector Dealings / Market Share Purchase
16th Sep 201911:18 amRNSDirector/PDMR Shareholding
16th Sep 20199:15 amRNSDirectors Dealings / Market Share Purchases
13th Sep 20192:57 pmRNSLong Term Incentive Plan Option Grant
13th Sep 20191:13 pmRNSDirectors Dealings / Market Share Purchases
13th Sep 201910:53 amRNSDirector Dealings / Market Share Purchase
4th Sep 20197:00 amRNSOxford Biomedica Interim Results
2nd Sep 20199:31 amRNSTotal Voting Rights
23rd Aug 201911:06 amRNSDirector Dealings / Market Share Purchase
9th Aug 201912:00 pmRNSNotice of Interim Results
1st Aug 20199:18 amRNSTotal Voting Rights
25th Jul 20192:17 pmRNSDirector Dealings / Market Share Purchase
1st Jul 201911:04 amEQSHardman & Co Research: Oxford BioMedica (OXB): Eying up long-term value
1st Jul 201910:01 amRNSBlock listing Interim Review
1st Jul 20199:32 amRNSTotal Voting Rights
28th Jun 20197:00 amRNSRepayment of Debt Facility
26th Jun 20192:52 pmRNSDirector Dealings / Market Share Purchase
26th Jun 20197:00 amRNSOXB and Santen enter R&D collaboration
25th Jun 20197:00 amRNSBoard Change
18th Jun 20197:15 amEQSHardman & Co Research: Oxford BioMedica (OXB): De-leveraging the balance sheet
10th Jun 20192:34 pmRNSDirector/PDMR Shareholding
6th Jun 20191:08 pmRNSAxovant update on 1st cohort of Sunrise-PD trial
6th Jun 201911:39 amRNSHolding(s) in Company
5th Jun 201912:06 pmRNSHoldings in Company
4th Jun 20195:38 pmRNSHoldings in Company
4th Jun 20199:59 amRNSTotal Voting Rights
3rd Jun 20196:06 pmRNSHolding(s) in Company
3rd Jun 201910:31 amRNSTotal Voting Rights
29th May 20196:19 pmRNSExercise of Subscription Option by Novo Holdings
29th May 20191:06 pmRNSResult of AGM
28th May 20197:00 amRNSStrategic Investment by Novo Holdings A/S
23rd May 20196:04 pmRNSDirector Dealings / Market Share Purchase
2nd May 20192:53 pmRNSLong Term Incentive Plan Option Grant
1st May 201912:52 pmRNSREPLACEMENT: Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.